Mangoceuticals (NASDAQ:MGRX) Stock Rating Upgraded by Wall Street Zen

Mangoceuticals (NASDAQ:MGRX) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mangoceuticals in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Mangoceuticals Stock Performance

Shares of Mangoceuticals stock opened at $0.52 on Friday. The company has a fifty day simple moving average of $0.40 and a 200-day simple moving average of $0.43. Mangoceuticals has a 12-month low of $0.16 and a 12-month high of $2.75. The stock has a market cap of $8.94 million, a price-to-earnings ratio of -0.35 and a beta of 2.28.

Mangoceuticals (NASDAQ:MGRX) last announced its quarterly earnings results on Tuesday, May 19th. The company reported ($0.22) EPS for the quarter. Mangoceuticals had a negative return on equity of 112.00% and a negative net margin of 4,639.13%.The company had revenue of $0.07 million for the quarter.

Institutional Trading of Mangoceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in Mangoceuticals by 35.4% during the 2nd quarter. Geode Capital Management LLC now owns 26,498 shares of the company’s stock worth $40,000 after acquiring an additional 6,928 shares during the period. Jane Street Group LLC acquired a new position in shares of Mangoceuticals in the fourth quarter valued at approximately $35,000. Armistice Capital LLC acquired a new position in shares of Mangoceuticals in the fourth quarter valued at approximately $1,137,000. Boothbay Fund Management LLC purchased a new stake in shares of Mangoceuticals during the fourth quarter worth approximately $28,000. Finally, Ikarian Capital LLC purchased a new stake in shares of Mangoceuticals during the fourth quarter worth approximately $102,000. 56.72% of the stock is owned by hedge funds and other institutional investors.

Mangoceuticals Company Profile

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.